JavaScript is disabled for your browser. Some features of this site may not work without it.
Cost-utility analysis of ramucirumab after sorafenib for hepatocellular carcinoma patients with alpha-fetoprotein concentration >400ng/ml in the Norwegian healthcare setting - selection of the optimal distribution